Osiris Misses on Q4 Earnings - Analyst Blog

By
A A A

Osiris Therapeutics Inc.'s ( OSIR ) fourth quarter 2013 earnings came in at 11 cents per share, compared to the year-ago loss of 2 cents per share. However, fourth quarter earnings missed the Zacks Consensus Estimate of $1.29 per share.

Revenues for the quarter came in at $8.1 million, missing the Zacks Consensus Estimate of $58 million but well above the year-ago quarter revenues of $2.9 million.

Full year earnings came in at 3 cents per share, compared to the year-ago loss of 18 cents per share and the Zacks Consensus Estimate of a loss of 21 cents per share. Revenues came in at $24.3 million, well above the year-ago revenues of $7.8 million. The Zacks Consensus Estimate was $73 million.

Quarterly Details

Research and development (R&D) expenses increased 62.4% from the year-ago period to $1.9 million. The company intends to study Grafix for the treatment of venous leg ulcers.

Selling, general and administrative expenses increased to $4.1 million from $1.7 million in the year-ago period reflecting investment in commercial activities. The company has increased its sales force significantly for the promotion of Grafix.

Meanwhile, in early Oct 2013, Osiris sold its culture-expanded mesenchymal stem cell (ceMSC) business including Prochymal (for up to $100 million) to a wholly-owned subsidiary of Mesoblast Limited. Osiris will be entitled to royalty payments as well.

Osiris also stated that the FDA does not require the company to file a biologic license application (BLA) for Grafix to remain on the market. However, the company intends to submit a BLA for enhanced label claims - discussions with the FDA are ongoing.

Osiris is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include companies like Alexion Pharmaceuticals, Inc. ( ALXN ), Gilead Sciences Inc. ( GILD ) and Alkermes plc ( ALKS ) - all three are Zacks Rank #1 (Strong Buy) stocks.



ALKERMES INC (ALKS): Free Stock Analysis Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

OSIRIS THERAPTC (OSIR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Earnings , Stocks

Referenced Stocks: ALKS , ALXN , GILD , OSIR

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

80,672,062
  • $15.11 ▼ 7.47%
66,542,096
  • $17.01 ▼ 0.12%
55,706,072
  • $23.65 ▲ 21.22%
52,954,494
  • $14.70 ▼ 10.69%
50,243,980
  • $14.70 ▼ 7.49%
47,401,468
  • $100.11 ▼ 0.64%
43,293,183
  • $4.95 ▼ 5.17%
36,328,194
  • $2.79 ▼ 1.41%
As of 9/29/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com